Colloral oral type II collagen to suppress T cells by oral tolerance data

AIMM (Lexington, Mass.) announced results of a Phase II multiple dose testing trial, showing efficacy with the 20 µg dose, with statistically significant improvement over placebo on the Paulus criteria.

Intent-to-treat analysis showed that 46 percent of patients given 20 µg of the oral collagen met this standard, compared to 28 percent of those receiving placebo. ...